Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Charles Schwab Investment Management Inc. acquired a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 156,784 shares of the company’s stock, valued at approximately $2,731,000. Charles Schwab Investment Management Inc. owned approximately 0.29% of Bicara Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in BCAX. Geode Capital Management LLC acquired a new position in Bicara Therapeutics during the third quarter worth about $1,239,000. Vestal Point Capital LP acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $10,825,000. FMR LLC purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at approximately $57,913,000. Braidwell LP acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at $42,219,000. Finally, Point72 Asset Management L.P. purchased a new position in Bicara Therapeutics during the third quarter worth $9,474,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BCAX. Cantor Fitzgerald restated an “overweight” rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. HC Wainwright raised their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Finally, Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research report on Thursday. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Bicara Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $36.50.

Bicara Therapeutics Price Performance

BCAX opened at $13.40 on Friday. Bicara Therapeutics Inc. has a 12 month low of $11.10 and a 12 month high of $28.09. The company has a 50-day simple moving average of $13.01.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, April 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). As a group, sell-side analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.